PHASE II TRIAL OF GEMCITABINE & TRIAPINE IN REFRACTORY METASTATIC BREAST CANCER

吉西他滨 II 期试验

• 批准号: 7375537
• 负责人: SHERRY MORGAN-MEADOWS
• 金额: $ 0.25万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375537
• 关键词: PHASE; II; TRIAL; GEMCITABINE; TRIAPINE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (from ClinicalTrials.gov website) Drugs used in chemotherapy, such as 3-AP (triapine) and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining 3-AP with gemcitabine may kill more tumor cells. This is a Phase II trial to study the effectiveness of combining 3-AP with gemcitabine in treating patients who have refractory metastatic breast cancer.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。化疗中使用的药物，如3-AP（曲平）和吉西他滨，以不同的方式阻止肿瘤细胞分裂，从而使它们停止生长或死亡。3-AP联合吉西他滨可杀死更多的肿瘤细胞。这是一项II期试验，旨在研究3-AP联合吉西他滨治疗难治性转移性乳腺癌患者的有效性。